Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Thumbnail Image
Download
Name

1-s2.0-S2211124718319272-main.pdf

Size

3.27 MB

Format

Adobe PDF

Checksum (MD5)

925fad18290c492f0dc91df1b81f49bf

Download all files submitted through automated deposit
sword-2019-02-28.original.zip (2.14 MB)
Author(s)
Fulciniti, Mariateresa
•
Lin, Charles Y.
•
Samur, Mehmet K.
•
Lopez, Michael A.
•
Singh, Irtisha
•
Lawlor, Matthew A.
•
Szalat, Raphael E.
•
Ott, Christopher J.
•
Avet-Loiseau, Herve’
•
Anderson, Kenneth C.
more
Date Issued
December 2018
Journal
Cell Reports
Publisher
Elsevier BV
Citation
Fulciniti, Mariateresa et al. “Non-Overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.” Cell Reports 25, 13 (December 2018): 3693–3705.e6 © 2018 Elsevier
Version
Final published version
Abstract
The relationship between promoter proximal transcription factor-associated gene expression and super-enhancer-driven transcriptional programs are not well defined. However, their distinct genomic occupancy suggests a mechanism for specific and separable gene control. We explored the transcriptional and functional interrelationship between E2F transcription factors and BET transcriptional co-activators in multiple myeloma. We found that the transcription factor E2F1 and its heterodimerization partner DP1 represent a dependency in multiple myeloma cells. Global chromatin analysis reveals distinct regulatory axes for E2F and BETs, with E2F predominantly localized to active gene promoters of growth and/or proliferation genes and BETs disproportionately at enhancer-regulated tissue-specific genes. These two separate gene regulatory axes can be simultaneously targeted to impair the myeloma proliferative program, providing an important molecular mechanism for combination therapy. This study therefore suggests a sequestered cellular functional control that may be perturbed in cancer with potential for development of a promising therapeutic strategy.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/128288
DOI of Published Version
https://doi.org/10.1016/j.celrep.2018.12.016
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.